Orthocell wins Chinese patent for Celgro

Orthocell (ASX:OCC) has secured a Chinese patent covering its Celgro collagen reconstructive platform technology.

The patent relates to the manufacture of bio-scaffolds to aid in the surgical repair of soft tissue injuries to tendons, cartilage and eardrums. It also covers the delivery of stem cells to the surgical site.

Orthocell has already been granted similar patents in Singapore and New Zealand. Managing Director Paul Anderson said the Chinese patent “further strengthens our global intellectual property position for our unique regenerative therapies”.

Celgro is designed to overcome or alleviate some major problems associated with commercially available bio-scaffolds, including immune reactions due to the presence of residual foreign cells.

Celgro uses a cell-free matrix free of contaminants or reactive DNA and has a tissue-friendly structure designed to facilitate tissue in-growth and repair.

“We believe Celgro collagen scaffold products are superior to other existing collagen products and offer widespread therapeutic and commercial potential with particular emphasis on orthopaedic and reconstructive applications, such as tendon, bone and soft tissue defect repair,” Anderson said.

Orthocell (ASX:OCC) shares were trading 2.44% lower at $0.40 as of around 1.30 pm on Monday.